| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | Per Pfeiffer | Q56839877 |
| Camilla Qvortrup | Q57617004 | ||
| P2093 | author name string | Sabine Tejpar | |
| P2860 | cites work | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 |
| A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
| Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. | Q33468432 | ||
| A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study | Q36097259 | ||
| ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer | Q38409832 | ||
| Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. | Q45948420 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 86-87 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Journal of gastrointestinal oncology | Q26842467 |
| P1476 | title | How to overcome resistance to therapy? | |
| P478 | volume | 3 |
Search more.